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Abstract Mechanical circulatory support (MCS) frequently
is used to treat medically refractory end-stage heart failure.
Initially designed to be a bridge to transplantation, MCS
also has proven itself as a durable therapy for patients who
are not transplant candidates. As outcomes for patients with
MCS have improved, research interest in device develop-
ment has flourished, with many new device types under
investigation. In addition to improvement of MCS devices,
investigational work continues to achieve appropriate
patient selection and complication management.
Keywords Mechanical circulatory support.Left
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Introduction
In the United States, there are more than 5 million people
with heart failure, and every year 500,000 people are newly
diagnosed; as such, 40-year-old individuals have a 20%
chance of developing heart failure during their lifetime [1￿￿].
It is estimated that 200,000 patients have American College
of Cardiology/American Heart Association (ACC/AHA)
stage D heart failure, which is defined as heart failure
symptoms refractory to standard treatment [2]. Despite many
advances in recent decades that have specifically antagonized
the neurohormonal cascade, improved synchrony, and
aborted sudden cardiac death, heart failure continues to carry
a grave prognosis. Patients with ACC/AHA stage D heart
failure have a mortality approaching 80% at 5 years [2]. Once
patients become dependent on inotropic therapy, their 1-year
survival plummets to less than 30% [3].
The ideal therapy for the management of heart failure
refractory to usual medical care continues to be cardiac
transplantation [4]. However, the woeful shortage of organs
has made this treatment option untenable for many who are
eligible [5￿￿]. Last year in the United States, approximately
5–10 people were on the waiting list for each of the 2200
heart transplants that were performed. In addition, hundreds
of thousands of patients who have severe end-stage heart
failurearenoteligibleforahearttransplantduetoconcomitant
multisystemdisease, uncontrolleddiabetes, continuedtobacco
use, or psychosocial limitations, but continue to deteriorate.
History of Mechanical Support Devices
The limitations of medical therapy to treat end-stage heart
failure, the lack of available organs, and the large number
of patients who do not qualify for transplantation despite
worsening heart failure symptoms all have spurred interest
in mechanical circulatory support (MCS). Initial reports of
mechanical support of the heart date to the 1950s, when the
work was spearheaded by the development and refinement
of cardiopulmonary bypass by Drs. John Gibbon, Walter
Lillehei, and John Kirklin. In 1964, the National Institutes
of Health instituted the artificial heart program to promote
interest in this nascent field. Soon thereafter, Dr. Michael
DeBakey [6] reported the first clinical use of a left
S. S. Shreenivas: M. Jessup
Department of Medicine, Cardiovascular Division,
University of Pennsylvania School of Medicine,
Philadelphia, PA, USA
J. E. Rame (*)
Medical Director Mechanical Assist Device Program,
Penn Heart and Vascular Center,
Hospital of the University of Pennsylvania,
Perelman 2 East Pavilion, 3400 Civic Center Boulevard,
Philadelphia, PA 19104, USA
e-mail: eduardo.rame@uphs.upenn.edu
Curr Heart Fail Rep (2010) 7:159–166
DOI 10.1007/s11897-010-0026-4ventricular assist device (LVAD); the competing group lead
by Dr. Adrian Kantrovitz [7] followed soon thereafter with
their own version.
First-Generation Mechanical Circulatory Support
The first-generation LVADs were pulsatile devices with
many moving parts that suffer from frequent device
complications; due to their size, these large devices are
associated with more frequent infections and are limited to
patients with a body surface area of 1.5 m
2 or greater.
In 1994, the US Food and Drug Administration (FDA)
approved the pulsatile ventricular assist device (VAD)
HeartMate XVE (later called HeartMate I; Thoratec
Corporation, Pleasanton, CA) as the first VAD for bridge
to transplantation [8]. The initial study involved 19 patients
who wereonmultipleinotropes,and84% requiredintra-aortic
balloon pumps (IABP). Of the initial 19 patients, 13 patients
were supported to transplantation after a mean wait time
of 66 days and three patients died of multisystem organ
failure (two of whom had significant right ventricular
[RV] dysfunction). The initial anticoagulation strategy
with the HeartMate XVE used aspirin with dipyridamole,
and no thrombotic events were reported in this study.
The overwhelming success of the HeartMate XVE as a
temporary support device to bridge patients to transplant
led to a growing interest in the use of this device as a
permanent therapy for long-term support as an alternative to
transplant. The Randomized Evaluation of Mechanical
Assistance in Treatment of Chronic Heart Failure (RE-
MATCH) study, which evaluated the HeartMate XVE
against medical therapy in patients with end-stage heart
failure, opened the door to the current explosion of interest
in mechanical support devices [9]. In this landmark study,
129 patients with New York Heart Association (NYHA)
class IV heart failure who were ineligible for heart
transplantation were randomized to receive a HeartMate
XVE or maximum medical therapy, which in the over-
whelming number of cases (> 70%) included intravenous
inotropic support. The patients who received the HeartMate
XVE had a 48% reduction in the risk of death from any
cause. The device group had an estimated 1-year survival of
52% compared with a 1-year survival in the medical therapy
group of 25%.
Despite gaining FDA approval, the HeartMate XVE was
not widely implanted outside transplant centers due to its
large size, the specialized care that all VADs require, and
frequent device failure after about 18 months of continued
use [10]. Although patients on MCS survived for an
average of 258 days longer, they also spent more than
2 months longer in the hospital. They also were more likely
to experience fatal outcomes such as sepsis, bleeding, and
device failure. In fact, 41% of deaths in the device cohort
were due to sepsis, and a further 17% of deaths were due to
device failure, with 10 of the original 68 patients requiring
device replacement. Follow-up of 280 patients who
underwent HeartMate XVE implantation between 2001
and 2005 yielded similar results to the original REMATCH
study [11]. The 1-year survival of these patients was 56%,
but the in-hospital mortality after surgery was fairly high at
27%. More disconcerting was that device failure again
played a major role in outcome, with 72.9% of patients at
2 years either requiring a device replacement or experiencing
a fatal event secondary to device failure. A nonrandomized
trial with another first-generation, positive displacement,
pulsatile device, the Novacor LVAS (WorldHeart, Ottawa,
Canada), also demonstrated improved survival with MCS
therapy compared with standard medical care. Use of this
device was associated with a significantly greater stroke risk:
62% of patients implanted with the Novacor LVAS suffered a
stroke or transient ischemic attack [12].
Second-Generation Mechanical Circulatory Support
The marked survival benefit documented in patients
implanted with these devices stimulated research in device
improvement and has lead to second- and third-generation
LVADs. Second-generation LVADs are continuous-flow
devices that work with an axial flow mechanism, such as
HeartMate II (Thoratec Corporation, Pleasanton, CA) [13],
Jarvik 2000 (Jarvik Heart, Inc., New York, NY) [14], and
HeartAssist 5 (MicroMed Cardiovascular, Houston, TX)
[15]). Due to the presence of a single moving rotor, device
wear and tear is less problematic. In addition to their
smaller size, second-generation devices require a more
limited surgery, are less likely to become infected, and can
be used more frequently in patients with small body surface
areas.
The HeartMate II was evaluated as a bridge to
transplantation in a prospective trial involving 133 patients
that were either status 1A or 1B for heart transplantation
[16]. At 6 months, 75% of patients (n=100) either had been
transplanted (n=56), continued with ongoing mechanical
support and were still listed for transplantation (n=43), or
achieved cardiac recovery leading to device explant (n=1).
Actuarial survival was 89% at 1 month, 75% at 6 months,
and 68% at 1 year. Interestingly, of the 43 patients who
remained eligible for cardiac transplantation, four patients
eventually removed themselves from the transplant list due
to preference for continued mechanical support. Within
the 6-month follow-up period, 25 patients (18%) died; of
these, 18 (13.5%) died during the initial hospitalization.
Fewer patients experienced device complications, with
only five patients (3.7%) requiring device replacement
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bleeding requiring surgery, sepsis, and stroke/transient
ischemic attack. Due to the higher thrombogenic potential of
the HeartMate II, these patients were maintained on warfarin
(with international normalized ratio [INR] goal 2.5–3.5) and
aspirin plus dipyridamole. Longer-term follow-up for
18 months in 281 patients with the HeartMate II as a bridge
to transplantation yielded similar results to the earlier study
[17]. In this trial, 72% of patients successfully underwent
transplantation (55.8%), achieved cardiac recovery and had
the device explanted (2.5%), or were still dependent on
mechanical support and listed for a heart transplant (19.9%).
Survival of these patients was even better than those in the
initial HeartMate II study with 82% alive at 6 months, 73%
alive at 12 months, and 72% alive at 18 months. Device-
related dysfunction causing death again was low at 3%
(n=7), and 11 patients required device replacement. The
most common complication continued to be bleeding,
which required surgery in 26% of patients. Infection
related to the percutaneous lead was present in 14% of
patients, and 2% of patients experienced a pump pocket
infection. Twenty-five (8.9%) patients experienced a
stroke, 15 of which were ischemic and 10 hemorrhagic;
40% of the strokes were fatal.
To further examine the efficacy of second-generation
LVADs compared with their first-generation counterparts, a
randomized trial of the HeartMate II versus the HeartMate
XVE was conducted during a 2-year period [18]. Patients
implanted with the HeartMate II were four times more
likely (46% vs 11%) to be alive at 2 years without a stroke
or another operation due to device complication. Only 10%
of patients with the continuous-flow LVAD required pump
replacement compared with 36% of patients with the
pulsatile HeartMate XVE. Of the 13 replacements of the
continuous-flow LVAD, 10 were due to percutaneous lead
disconnect/breakage, and a further two patients experienced
pump thrombosis. The risk of stroke did not differ between
the two cohorts, but the HeartMate II group was treated
with aspirin and warfarin with a goal INR of 2.0–3.0,
whereas the HeartMate XVE group was treated with aspirin
alone. Despite the greater anticoagulation, the risk of
overall bleeding did not differ between the two groups,
although 30% of patients with the continuous-flow LVAD
did experience bleeding that required surgery. The 11%
survival free from these two complications at 18 months in
the HeartMate XVE cohort was lower than the 23%
survival reported in the previously described REMATCH
study; this might be explained by the fact that the end point
in the REMATCH study did not account for survival free
from these complications. In this most recent study, the
2-year actuarial survival rate for the pulsatile LVAD was
24%, which matches up well with the results from
REMATCH. The 2-year actuarial survival in the continuous
LVAD cohort was 58%, more than twice that of the pulsatile
LVAD cohort. Also of interest was the finding that, although
the patients enrolled in this trial were initially deemed
ineligible for transplant, 17 patients with the HeartMate II
and 9 patients treated with the HeartMate XVE eventually
were transplanted once their contraindications to transplant
had resolved. Based on these data, the HeartMate II and
other second-generation LVADs have gained much wider
acceptance. A standardized protocol reviewing issues
such as anticoagulation and how to deal with LVAD
complications has been published recently to address this
growing population and the clinicians who must care for
the patients [19￿￿].
Third-Generation Mechanical Circulatory Support
Although outcomes with second-generation LVADs continue
to improve, several trials already are underway evaluating
third-generation LVADs including HeartWare HVAD,
[20], HeartMate III [21] (both manufactured by Thoratec
Corporation, Pleasanton, CA), and Synergy (CircuLite,
Inc., Saddle Brook, NJ) [22]. Third-generation LVADs
continue the trend of providing continuous blood flow but
differ from their second-generation counterparts by having a
“bearing-less” mechanism for moving blood, usually a
magnetically levitated impeller. In addition, these devices
continue the march toward miniaturization, with the smallest
device in current trials being the size of an AA battery [22].
Patient Selection
Using a classification of clinical intent at the time of
implantation, there are four broad indications for an LVAD.
The most common indication, the bridge-to-transplant
intent, is performed on someone who needs to be supported
while awaiting a transplant. The second indication, known
as destination therapy, applies to patients with refractory
heart failure symptoms who have contraindications for
transplant and require MCS. In the third category, bridge to
decision, patients have an imminent need for MCS but their
candidacy for transplantation requires a reevaluation of
parameters that can change with adequate support and
improvement of end-organ perfusion. A fourth category,
bridge to myocardial recovery, involves the application of
active mechanical unloading of the systemic ventricle,
exclusivelyinnonischemicheartfailure,torestoremyocardial
functiontoalevelthatcansustaintheindividualwithminimal
or no heart failure symptoms after the explantation of the
LVAD. Although it was initially thought that the first two
categories would be comprised of two completely separate
patient populations, it has become apparent that a significant
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transplant or destination therapy, either due to improvement
in their comorbidities (eg, obesity, pulmonary hypertension,
liver failure) while supported with an LVAD, or because they
suffer a complication (eg, stroke, infection) while being
supported and then are deemed unsuitable for a transplant.
Understandably, the decision to embark on mechanical
support for a patient with a failing heart is a difficult one,
and the criteria for referral vary greatly from institution to
institution. The initial MCS trials followed patients who
were being bridged to transplant and for whom mechanical
support was deemed to be their only option of surviving
until a heart became available. Once REMATCH results
became available, the push for replacing chronic inotropic
therapy with mechanical support gained momentum [23].
The results of the REMATCH trial clearly outlined the
marked survival advantage of LVADs over chronic intrave-
nous inotropes. Indeed, since REMATCH, there have been no
randomized trials proposed that would examine any of the
newer LVADs compared with chronic ionotropic therapy due
to the belief that doing so would be unethical. However,
thousands of patients continue to be maintained on intrave-
nous inotropes as both a bridge to transplant and also as
destination therapy. Other than patient preference withrespect
to quality-of-life issues [24], one of the key determinants in
deciding to pursue an LVAD is the significant morbidity
related to the actual surgery. The REMATCH cohort had
perioperative mortality of 31%, although as experience
with both the surgery and postoperative care has
improved, a few centers have reported perioperative mortality
as low as 8.7% [25].
An important next step after defining the patient
population that would benefit from mechanical support is
to calculate individual risk during the actual surgery, as
patients with severe RV failure and end-organ dysfunction
have a high in-hospital mortality after VAD surgery [26].
Lietz et al. [11, 27￿￿] examined 280 patients receiving the
HeartMate XVE as a destination device and derived a risk
score that divided patients into high- and low-risk groups
based on platelet count, serum albumin, INR, mean
pulmonary artery pressure, aspartate aminotransferase,
hematocrit, blood urea nitrogen, and whether they were
being treated with vasodilatory therapy or with intravenous
inotropes. Patients in the low-risk group had a survival to
discharge of 93.7% compared with a survival to discharge
of 13.7% in the very high–risk group. The low-risk group
had a 1-year survival of 81.2% compared with a 1-year
survival of 10.7% for the very high–risk group. Analysis of
this patient population affirms that the presence of
comorbidities (ie, renal and hepatic dysfunction), RV
dysfunction (ie, low pulmonary artery pressure and eleva-
tion in liver enzymes), and poor nutritional status greatly
increase mortality, which in most cases was secondary to
sepsis (29.5%), multisystem organ failure (12.8%), stroke
(9%), and right heart failure (8.4%). Interestingly, the
severity of heart failure alone was not predictive of
mortality. Due to frequent hepatic dysfunction and high
perioperative bleeding risk, another group described the
ability of the Model for End-Stage Liver Disease (MELD)
score to predict perioperative and 6-month mortality with
LVAD placement [28]. Patients with an MELD score
greater than 17 had a 6-month mortality that was 2.5 times
higher than those with an MELD score less than 17. Both
of the above studies primarily looked at patients with first-
generation LVADs. A single-center (n=86) comparative
analysis examining the ability of various risk indices (Leitz-
Miller, Columbia, Acute Physiology and Chronic Health
Evaluation II [APACHE II], Interagency Registry for
Mechanically Assisted Circulatory Support [INTERMACS],
and Seattle Heart Failure Model [SHFM]) to predict mortality
withthenewercontinuous-flowHeartMateIIrevealedthatthe
SHFM was superior to the other risk indices in this specific
patient cohort [29].
Outcomes
As the perioperative risk with LVAD implantation has
improved, less sick patients are being considered for LVAD
placement. Though a less sick patient cohort might tolerate
surgery much better than a patient in cardiogenic shock, the
immediate survival advantage from mechanical support
might not be as obvious. Nevertheless, significant improve-
ment in functional capacity could be achieved if a detailed
evaluation is performed to identify patients who might derive
symptomatic and survival benefit without prohibitive risk.
Consideration for LVAD placement has been advocated
for patients with a 1-year life expectancy of less than
50% due to the severity of their heart failure and/or
symptoms that limit ambulation to less than one block
[23]. To further study outcomes in patients with different
disease severity, INTERMACS has defined seven different
profiles of end-stage heart failure [30]. The profiles range
from patients in critical cardiogenic shock to patients with
advanced NYHA class III symptoms (Table 1).
The INTERMACS dataset includes follow-up for all
MCS devices implanted in the United States since June 23,
2006 [31￿￿]. Centralization of these data allows for long-term
follow-up and device comparison, and serves as a historical
record for the evolution of MCS. The second annual
INTERMACSreportreviewed1092primaryLVADimplants,
and currently, there are more than 2500 patients included in
the registry. A full 85% of these patients are INTERMACS
profile 1 through 3, although the proportion of profile 1
patients has been decreasing as the expansion of LVAD use to
a less sick population increases. In addition, the first annual
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who were implanted in critical cardiogenic shock, or patient
profile1.Atthetimeofthesecondannualreport,therealready
was a shift toward the use of continuous-flow devices, with
51.6% of all LVAD implants registered as the newer
continuous-flow models. That trend has continued with the
current registry being comprised of more than 80%
continuous-flow models. The 1-year survival for all LVADs
has continued to improve, from the roughly 50% 1-year
survival reported in REMATCH to 74% reported in the
second annual INTERMACS report. Based on data presented
atthe International Society ofHeart and Lung Transplantation
annual meeting in 2010, the current 1-year survival for
LVADs has continued to improve and is now close to 85%
(Kirklin, unpublished data). The risk factors for mortality
identified in this registry include age of the recipient, RV
function, implantation in INTERMACS patient profile 1
patients, and the use of a pulsatile pump. The improved
mortality over the years can be explained by better
patient selection, standardized postimplantation care, and
more durable devices. However, despite the better out-
comes, a few common complications continue to plague
MCS devices.
Right Ventricular Failure
One of the main determinants of outcome after LVAD
implantation is RV function, which plays a role in
postoperative vasopressor requirements and multisystem
organ failure. A definition for RV failure in the setting of
left-sided MCS has not been fully developed, especially in
patients who develop signs and symptoms several months
postoperatively. However, perioperatively, a clinically
importantdefinitionthathasbeenembracedbyINTERMACS
is the need for RV mechanical support (RVAD) or persistent
need of inotropic support for more than 14 days. Clinically
important RV failure with compromised perfusion and
function of end organs remains a significant factor impacting
short- and long-term survival. In a single-center study of
patients with right heart failure, the abovementioned
definition identified that 35% of patients implanted with
HeartMate VXE and 41% of patients implanted with
HeartMate II met the criteria for RV failure, with significantly
fewer patients who were implanted with the HeartMate II
requiring support with a RVAD [32]. An RV-failure risk
score comprised of aspartate aminotransferase, bilirubin,
creatinine, and a preoperative vasopressor requirement
was able to identify patients at high risk for needing
biventricular support and a higher postoperative mortality
[33]. However, even the lowest risk group in this study
had a 20% incidence of RV failure (compared with an 80%
incidence in the highest risk group). A retrospective
review of the patients in the HeartMate II bridge-to-
transplant trial showed that patients with a central venous
pressure/pulmonary capillary wedge pressure ratio more
than 0.63, preoperative ventilator support, and elevated
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RV failure [34]. This study reported 20% of patients with
RV failure requiring either an RVAD (6%), early inotropic
support (7%), or late inotropic support (7%) and identified
a significant survival advantage in the patients who did not
develop clinically significant right heart failure. Single-center
studies have identified RV stroke work index, pulmonary
artery pressure, prior cardiac surgery, serum creatinine, and
systolic blood pressure as being predictive of post-LVAD RV
failure (Table 2)[ 35, 36]. Further work needs to be done to
truly identify risk factors predictive of RV failure post-LVAD
implantation. Perhaps better techniques of RV protection
during LVAD implantation need to be further explored as
well.
Infection
As in the REMATCH and HeartMate II bridge-to-transplant
and destination therapy trials, the INTERMACS registry
identified infection as a common adverse event and the
cause of death in 16.2% of patients. The newer continuous-
flow devices are much smaller and, as the HeartMate II
trials showed, these newer devices are associated with less
pocket and driveline infections, which had been a source of
morbidity and mortality. Once a driveline infection is
identified, attempts to treat it with antibiotics can be
successful, but the recurrence and possibility of bacterial
resistance to antibiotics also have been noted. Anecdotally,
cases of pump and other thrombosis postinfection have led
to concern that a postinfectious hypercoagulable state can
lead to clinically important events in LVAD recipients.
Attempts to stabilize the driveline with support devices that
minimize driveline movement, and thus minimize skin
irritation, also have been reported to minimize driveline
infections.
Table 1 INTERMACS classification of heart failure
Level 1 Critical cardiogenic shock (“crashing and burning”)
Level 2 Progressive decline on inotropic support
Level 3 Stable but inotrope dependent
Level 4 Resting symptoms on home oral therapy
Level 5 Exertion intolerant
Level 6 Exertion limited
Level 7 Advanced NYHA class III
INTERMACS Interagency Registry for Mechanically Assisted Circula-
tory Support, NYHA New York Heart Association.
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Both ischemic and hemorrhagic stroke have been associated
with MCS. A primary cerebrovascular event was associated
with 14.1% of all deaths in the second annual INTERMACS
report [31￿￿]. With the advent of the continuous-flow
devices, standard practice has been the use of aspirin and
concomitant use of warfarin (goal INR 2.5–3.5 initially, but
now 1.5–2.5) [19]. A heparin bridge frequently is used
whenever a patient is subtherapeutic, either immediately
after implant or before an invasive procedure. Recent data
from Slaughter et al. [37] suggest that a heparin bridge might
not be needed at all immediately after LVAD implantation.
The appropriate anticoagulation regimen that minimizes
the risk of bleeding and prevents thromboembolism has
yet to be demonstrated conclusively. A tailored approach
for thromboprophylaxis with thromboelastography has
been reported by several centers, but a prospective
multicenter study has yet to be performed. In addition
to anticoagulation, the aforementioned hypercoagulable
state associated with infection could be playing a role in
causing ischemic strokes. Finally, one of the leading
causes of hemorrhagic stroke in the general population is
the presence of systemic hypertension. Patients with
continuous-flow devices have increased diastolic pressure
at higher pump speeds and it is becoming increasingly
clear that direct Doppler measurement should be used to
measure systemic blood pressure (systolic blood pressure
approximates the mean with a narrow pulse pressure) and
that target blood pressure should be lower. It is our
practice to aim for a mean blood pressure no greater than
80 mm Hg and to decrease pump speed or increase the
degree of afterload reduction if the mean pressure is
higher than 90 mm Hg. However, there are no retrospec-
tive or prospective data linking high mean blood pressure
on a continuous-flow device and a greater incidence of
hemorrhagic stroke.
Bleeding
Bleeding, both at the site of implantation and in the
gastrointestinal (GI) tract, is another frequent adverse event
associated with MCS devices. The second INTERMACS
annual report showed that bleeding was the second most
frequent adverse event (after infection) [31￿￿]. Despite this,
the bleeding episodes were infrequently fatal and accounted
for only 6.7% of all deaths. There have been reports that the
use of continuous-flow devices leads to acquired von
Willebrand’s deficiency, which predisposes to bleeding,
especially in the setting of antiplatelet use [38]. Also, the
use of continuous-flow devices has led to more frequent
incidence of atrioventricular fistulas in the GI tract, a
finding also seen in another narrow pulse state, aortic
stenosis [39]. As the appropriate anticoagulation strategy
evolves with lower INR goals, less frequent use of heparin,
and a reevaluation of the role of antiplatelet use, it is likely
that these adverse events will become less frequent.
Conclusions
MCS has evolved from a therapy of last resort to rescue
patients in postoperative cardiogenic shock to a viable
alternative for thousands of patients with end-stage heart
failure. The INTERMACS registry allows for centralization
of data gathering for the MCS field and already has
depicted remarkable trends both in device development
and in tracking adverse effects. Additional registries in
multiple European nations have been started, and hopefully,
an international registry that will allow for the compilation
of all data regarding MCS will one day be a reality. In the
meantime, progress continues in miniaturization of circula-
tory support devices that will lead to better operative
outcomes, less frequent infections, and higher patient
satisfaction.
Table 2 Predictors of right ventricular heart failure
Study Predictors Comments
Matthews et al. [34] Vasopressor requirement; Aspartate aminotransferase >
80 IU/L; Bilirubin > 2.0 mg/dL; Creatinine > 2.3 mg/dL
197 patients; 86% pulsatile devices; 20% of
patients with a low (normal) score still
experienced RV failure
Kormos et al. [35] (HeartMate
II
a bridge-to-transplant trial)
Central venous pressure/pulmonary capillary wedge
pressure ratio > 0.63; Preoperative ventilator support;
Blood urea nitrogen > 39 mg/dL
484 patients; all HeartMate II (continuous flow)
devices
Fitzpatrick et al. [36] Severe preoperative RV dysfunction; RV stroke work
index ≤ 0.25 mm Hg/L/m
2; Creatinine ≥ 1.9 mg/dL;
Prior cardiac surgery; Systolic blood pressure ≤ 96 mm
Hg; Cardiac index ≤ 2.2 L/min/m
2
266 patients; 96% pulsatile devices; risk score
comprising all of these variables had 83%
sensitivity and 80% specificity for predicting
the success of isolated LVAD support
aManufactured by Thoratec Corporation, Pleasanton, CA.
LVAD left ventricular assist device, RV right ventricular.
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